{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:59:46Z","timestamp":1789106386327,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a small- to medium-vessel necrotising vasculitis and eosinophilic inflammation. Mepolizumab, an anti-interleukin-5 (IL-5) monoclonal antibody has been approved in Japan since 2018 for refractory EGPA treatment. Benralizumab, an anti-IL-5 receptor monoclonal antibody, also has been reported to reduce the glucocorticoid dose in patients with refractory EGPA. On the other hand, several investigators have demonstrated new-onset EGPA under biologics, and it is unclear whether this treatment for severe allergic diseases can prevent the development of EGPA. Herein, we report a case of new-onset EGPA under benralizumab treatment. The patient had fever, weight loss, muscle pain, and paraesthesia, the serum eosinophil count was 0\/\u03bcL, and the biopsy showed necrotizing vasculitis without eosinophilic infiltration. She was diagnosed as having EGPA and treated with high-dose glucocorticoid and intravenous cyclophosphamide, with a good response. Our case report indicates that anti-IL-5 agents may mask the development of EGPA and clinicians should be aware of the development of EGPA during anti-IL-5 agents.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad028","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T14:03:24Z","timestamp":1685196204000},"page":"145-149","source":"Crossref","is-referenced-by-count":7,"title":["New-onset of\u00a0eosinophilic granulomatosis with polyangiitis without eosinophilia and\u00a0eosinophilic infiltration under benralizumab treatment: A case report"],"prefix":"10.1093","volume":"8","author":[{"given":"Haruka","family":"Yonezawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu , Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu , Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu , Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu , Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"2023122911393038800_R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of\u00a0Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023122911393038800_R2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"EGPA Mepolizumab Study Team. Mepolizumab or placebo for\u00a0eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2023122911393038800_R3","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in\u00a0eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023122911393038800_R4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and\u00a0clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023122911393038800_R5","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.jaip.2020.04.006","article-title":"Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab","volume":"8","author":"Ho\u010devar","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023122911393038800_R6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and\u00a0validation of\u00a0a consensus methodology for\u00a0the classification of\u00a0the ANCA-associated vasculitides and\u00a0polyarteritis nodosa for\u00a0epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023122911393038800_R7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of\u00a0Rheumatology\/European Alliance of\u00a0Associations for\u00a0Rheumatology Classification Criteria for\u00a0Eosinophilic Granulomatosis with Polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023122911393038800_R8","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and\u00a0validation of\u00a0the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023122911393038800_R9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of\u00a0the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"key":"2023122911393038800_R10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.autrev.2015.10.006","article-title":"Dividing the Janus vasculitis? Pathophysiology of\u00a0eosinophilic granulomatosis with polyangitis","volume":"15","author":"Chaigne","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2023122911393038800_R11","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of\u00a0benralizumab on\u00a0airway eosinophils in\u00a0asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2023122911393038800_R12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.alit.2022.08.004","article-title":"Development of\u00a0vasculitis in\u00a0a case with severe asthma treated with benralizumab and\u00a0low-dose corticosteroid","volume":"72","author":"Umezawa","year":"2023","journal-title":"Allergol Int"},{"key":"2023122911393038800_R13","article-title":"Emergence of\u00a0extrathoracic manifestations of\u00a0eosinophilic granulomatosis with polyangiitis during benralizumab treatment","volume":"5","author":"Lim","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2023122911393038800_R14","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/rheumatology\/keaa572","article-title":"Onset of\u00a0eosinophilic granulomatosis with polyangiitis in\u00a0a patient treated with an IL-5 pathway inhibitor for\u00a0severe asthma","volume":"60","author":"Caminati","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023122911393038800_R15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12026-022-09317-5","article-title":"New-onset eosinophilic granulomatosis with polyangiitis in\u00a02 patients during treatment with IL-5 pathway inhibitors","volume":"70","author":"Holubar","year":"2022","journal-title":"Immunol Res"},{"key":"2023122911393038800_R16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.41986","article-title":"2022 American College of\u00a0Rheumatology\/European Alliance of\u00a0Associations for\u00a0Rheumatology Classification Criteria for\u00a0Granulomatosis With Polyangiitis","volume":"74","author":"Robson","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad028\/50512375\/rxad028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/145\/54920248\/rxad028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/145\/54920248\/rxad028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:28:22Z","timestamp":1703852902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/1\/145\/7181261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,27]]},"published-print":{"date-parts":[[2023,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad028","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,5,27]]}}}